Cyproheptadine for intrathecal baclofen withdrawal

Archives of Physical Medicine and Rehabilitation

Volumn 84, Issue 5, 2003, Pages 638-642

  Meythaler, Jay M ^a   Roper, James F ^b   Brunner, Robert C ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Baclofen; Cyproheptadine; GABA B; Hyperpyrexia; Implantable; Infusion pumps; Malignant; Muscle spasticity; Neuroleptic malignant syndrome; Receptor; Rehabilitation; Serotonin; Syndrome; Withdrawal symptoms

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; CYPROHEPTADINE; DIAZEPAM; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BOLUS INJECTION; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; INFUSION PUMP; MALE; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PRURITUS; SEROTONINERGIC SYSTEM; SPASTICITY; SPINAL CORD INJURY; WITHDRAWAL SYNDROME;

EID: 0037991460     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(03)00105-9     Document Type: Article

References (31)

1. Meythaler JM, Guin-Renfroe S, Brunner RC, Johnson A, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099-119.
2. Meythaler JM, McCary A, Hadley MN. Prospective study on the use of continuously infused intrathecal baclofen for spasticity due to acquired brain injury: a preliminary report. J Neurosurg 1997; 87:415-9.
3. Meythaler JM, Renfroe SG, Grabb PA, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic/dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil 1999;80:13-9.
4. Coffey RJ, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
5. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001;39:413-9.
6. Meythaler JM, Steers WD, Tuel SM, Cross LL, Haworth CS. Continuous intrathecal baclofen in spinal cord spasticity: a prospective study. Am J Phys Med Rehabil 1992;71:321-7.
7. Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadley MN. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 2001;82:155-61.
8. Meythaler JM. Use of intrathecally delivered medications for spasticity and dystonia in acquired brain injury. In: Yaksh TL, editor. Spinal drug delivery. New York: Elsevier; 1999. p 513-54.
9. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83:735-41.
10. Al-Khodairy AT, Vuagnat H, Uebelhart D. Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure. A case report. Am J Phys Med Rehabil 1999;78:272-7.
11. Green LB, Nelson VS. Death after acute withdrawal of intrathecal baclofen: case report and literature review. Arch Phys Med Rehabil 1999;80:1600-4.
12. Coffey RJ, Ridgely P. Abrupt intrathecal baclofen withdrawal: management of potentially life-threatening sequelae. Neuromodulation 2001;4:142-6.
13. Meythaler JM. Physiology of spastic hypertonia. Phys Med Rehabil Clin North Am 2001;12:725-32.
14. Barker I, Grant IS. Convulsions after abrupt withdrawal of baclofen. Lancet 1982;2:556-7.
15. Garabedian-Ruffalo SM, Ruffalo RL. Adverse effects secondary to baclofen withdrawal. Drug Intell Clin Pharmacol 1985;19: 304-6.
16. Grenier B, Mesli A, Cales J, Castel JP, Maurette P. Hyperthermie grave liée á un severage brutal de baclofène administré de faqon continue par voie intrathéscale. Ann Fr Anesth Reanim 1996;15: 659-62.
17. Harrison SA, Wood CA. Hallucinations after preoperative baclofen discontinuation in spinal cord injury patients. Drug Intell Clin Pharmacol 1985;19:747-9.
18. McRae AL, Brady KT, Sonne SC. Alcohol and substance abuse. Med Clin North Am 2001;85:779-801.
19. Mills KC. Serotonin syndrome: a clinical update. Crit Care Clin 1997;13:763-83.
20. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000;16:317-25.
21. Mueller PD, Korey WS. Death by "ecstasy": the serotonin syndrome? Ann Emerg Med 1998;32:377-80.
22. David WS. Myoglobinurea. Neurol Clin 2000;18:215-43.
23. Ramcharan S, Meenhorst PL, Otten JM, et al. Survival after massive ecstasy overdose. J Toxicol Clin Toxicol 1998;36:727-31.
24. Wilkinson W, Meythaler JM, Guin-Renfroe S. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj 1999;13:1025-31.
25. Meythaler JM, Stinson AM. Fever of central origin in traumatic brain injury controlled with propranolol. Arch Phys Med Rehabil 1994;75:816-8.
26. Physicians' desk reference. 55th ed. Montvale: Medical Economics; 2001. Periactin; p 1993-4.
27. Nance P, Meythaler JM. Intrathecal drug therapy. Phys Med Rehabil Clin North Am 1999;10:385-402.
28. Nance P. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. Phys Med Rehabil Clin North Am 2001;12:889-905.
29. Bose P, Parmer R, Parker J, Hayes RL, Thompson FJ. Traumatic brain injury (TBI)-induced spasticity: monoamine changes and possible mechanism [abstract]. J Neurotrauma 2002;19:1305.
30. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
31. Penn RD, Savoy SM, Corcos DM, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-22.